Delix Therapeutics

Delix's Non-Hallucinogen Completes Safe Administration To First Clinical Trial Cohort

Delix's Non-Hallucinogenic Psychoplastogen Enters Phase 1 Trial

Delix: Elucidating How Psychedelics Actually Induce Neuroplasticity Vs. SSRIs

Delix's Non-Hallucinogenic Psychoplastogen Enters Phase 1 Trial

Delix: Elucidating How Psychedelics Actually Induce Neuroplasticity Vs. SSRIs

Delix Inks Deal With Cellectricon; Psyched Wellness Partners With Spacestation

Psychedelics Companies Share Corporate Updates: Numinus, Delix, Tryp And Small Pharma

Delix Inks Deal With Cellectricon; Psyched Wellness Partners With Spacestation

Psychedelics Companies Share Corporate Updates: Numinus, Delix, Tryp And Small Pharma

Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS

Delix Therapeutics Raises $30M In Convertible Note Financing, Will Enhance Drug Development Program

Delix Therapeutics Recent News

National Institute on Drug Abuse Will Test Ibogaine For Addiction Treatment As Drug Deaths Crest 100,000

The U.S. government has taken a significant step toward tackling the mounting national substance addiction crisis by partnering with neuroscience company Delix Therapeutics to study a non-hallucinogenic version of the psychedelic drug ibogaine.

Psyched: Elon Musk Discusses Psychedelics, Delix Raises $70M, MindCure To Study MDMA In Female Sexual Dysfunction

The Week In Psychedelics:

'Psychedelics Without Hallucinations': Concept Gets Closer To Human Trials With $70M Funding

Delix Therapeutics, a drug development company in the psychedelics space, has closed a $70 million Series A financing round.